{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,25]],"date-time":"2025-05-25T18:40:03Z","timestamp":1748198403672,"version":"3.41.0"},"reference-count":55,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,9]]},"abstract":"<jats:sec>\n            <jats:title>Purpose of review<\/jats:title>\n            <jats:p>The purpose of this review is to provide clear guidance to health professionals delivering chimeric antigen receptor T-cell (CAR-T) therapy on the best supportive management throughout the CAR-T pathway, from referral to long-term follow-up, including psychosocial aspects.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Recent findings<\/jats:title>\n            <jats:p>CAR-T therapy has changed the treatment landscape for relapsed\/refractory (r\/r) B-cell malignancy. Approximately 40% of r\/r B-cell leukaemia\/lymphoma patients receiving CD19-targeted CAR-T therapy achieve durable remission following a single dose. The field is rapidly expanding to encompass new CAR-T products for indications such as multiple myeloma, mantle cell lymphoma and follicular lymphoma, and the number of patients eligible to receive CAR-T therapy is likely to continue to grow exponentially. CAR-T therapy is logistically challenging to deliver, with involvement of many stakeholders. In many cases, CAR-T therapy requires an extended inpatient hospital admission, particularly in older, comorbid patients, and is associated with potentially severe immune side effects. Further, CAR-T therapy can lead to protracted cytopenias that can last for several months accompanied by a susceptibility to infection.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Summary<\/jats:title>\n            <jats:p>For the reasons listed above, standardised, comprehensive supportive care is critically important to ensure that CAR-T therapy is delivered as safely as possible and that patients are fully informed of the risks and benefits, as well as the requirement for extended hospital admission and follow-up, to fully realise the potential of this transformative treatment modality.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/spc.0000000000000657","type":"journal-article","created":{"date-parts":[[2023,7,7]],"date-time":"2023-07-07T19:59:02Z","timestamp":1688759942000},"page":"231-239","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Supportive care for chimeric antigen receptor T-cell patients"],"prefix":"10.1097","volume":"17","author":[{"given":"Deborah","family":"Springell","sequence":"first","affiliation":[{"name":"Department of Haematology, University College London Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maeve","family":"O\u2019Reilly","sequence":"additional","affiliation":[{"name":"Department of Haematology, University College London Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4901-5858","authenticated-orcid":false,"given":"Claire","family":"Roddie","sequence":"additional","affiliation":[{"name":"Department of Haematology, University College London Hospital"},{"name":"Research Department of Haematology, University College London, London, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2023,7,7]]},"reference":[{"key":"R1-20250525","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N Engl J Med"},{"key":"R2-20250525","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/S1470-2045(21)00591-X","article-title":"Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial","volume":"23","author":"Jacobson","year":"2022","journal-title":"Lancet Oncol"},{"key":"R3-20250525","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N Engl J Med"},{"key":"R4-20250525","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"N Engl J Med"},{"key":"R5-20250525","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1038\/s41591-021-01622-0","article-title":"Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial","volume":"28","author":"Fowler","year":"2022","journal-title":"Nat Med"},{"key":"R6-20250525","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1056\/NEJMoa1914347","article-title":"KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma","volume":"382","author":"Wang","year":"2020","journal-title":"N Engl J Med"},{"key":"R7-20250525","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/S0140-6736(21)01222-8","article-title":"KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study","volume":"398","author":"Shah","year":"2021","journal-title":"Lancet Lond Engl"},{"key":"R8-20250525","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S0140-6736(20)31366-0","article-title":"Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study","volume":"396","author":"Abramson","year":"2020","journal-title":"Lancet"},{"key":"R9-20250525","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1056\/NEJMoa2024850","article-title":"Idecabtagene vicleucel in relapsed and refractory multiple myeloma","volume":"384","author":"Munshi","year":"2021","journal-title":"N Engl J Med"},{"key":"R10-20250525","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/S0140-6736(21)00933-8","article-title":"Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b\/2 open-label study","volume":"398","author":"Berdeja","year":"2021","journal-title":"Lancet Lond Engl"},{"key":"R11-20250525","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1038\/s41586-022-04489-4","article-title":"GD2-CAR T cell therapy for H3K27M-mutated diffuse midline gliomas","volume":"603","author":"Majzner","year":"2022","journal-title":"Nature"},{"key":"R12-20250525","doi-asserted-by":"crossref","first-page":"2561","DOI":"10.1056\/NEJMoa1610497","article-title":"Regression of glioblastoma after chimeric antigen receptor T-cell therapy","volume":"375","author":"Brown","year":"2016","journal-title":"N Engl J Med"},{"key":"R13-20250525","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.annonc.2021.12.003","article-title":"Management of adults and children receiving CAR T-cell therapy: 2021 best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE) and the European Haematology Association (EHA)","volume":"33","author":"Hayden","year":"2022","journal-title":"Ann Oncol"},{"key":"R14-20250525","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/nrclinonc.2017.148","article-title":"Chimeric antigen receptor T-cell therapy \u2013 assessment and management of toxicities","volume":"15","author":"Neelapu","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"key":"R15-20250525","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1182\/blood-2017-07-793760","article-title":"Infectious complications of CD19-targeted chimeric antigen receptor-modified T-cell immunotherapy","volume":"131","author":"Hill","year":"2018","journal-title":"Blood"},{"key":"R16-20250525","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1182\/blood.2019004000","article-title":"How I prevent infections in patients receiving CD19-targeted chimeric antigen receptor T cells for B-cell malignancies","volume":"136","author":"Hill","year":"2020","journal-title":"Blood"},{"key":"R17-20250525","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1111\/bjh.18209","article-title":"A national service for delivering CD19 CAR-Tin large B-cell lymphoma \u2013 the UK real-world experience","volume":"198","author":"Kuhnl","year":"2022","journal-title":"Br J Haematol"},{"key":"R18-20250525","first-page":"349","article-title":"GLA\/DRST real-world outcome analysis of CAR-T cell therapies for large B-cell lymphoma in Germany","volume":"140","author":"Bethge","year":"2022","journal-title":"Blood"},{"key":"R19-20250525","doi-asserted-by":"crossref","first-page":"3970","DOI":"10.1182\/bloodadvances.2022007006","article-title":"Primary progression during frontline CIT associates with decreased efficacy of subsequent CD19 CAR T-cell therapy in LBCL","volume":"6","author":"Perez","year":"2022","journal-title":"Blood Adv"},{"key":"R20-20250525","doi-asserted-by":"crossref","first-page":"2872","DOI":"10.1182\/bloodadvances.2022009019","article-title":"Effective bridging therapy can improve CD19 CAR-T outcomes while maintaining safety in patients with large B-cell lymphoma","volume":"7","author":"Roddie","year":"2023","journal-title":"Blood Adv"},{"key":"R21-20250525","doi-asserted-by":"crossref","first-page":"2871","DOI":"10.1182\/bloodadvances.2020001837","article-title":"Bridging therapy prior to axicabtagene ciloleucel for relapsed\/refractory large B-cell lymphoma","volume":"4","author":"Pinnix","year":"2020","journal-title":"Blood Adv"},{"key":"R22-20250525","doi-asserted-by":"crossref","first-page":"3773","DOI":"10.1182\/blood.V126.23.3773.3773","article-title":"Addition of fludarabine to cyclophosphamide lymphodepletion improves in vivo expansion of CD19 chimeric antigen receptor-modified T cells and clinical outcome in adults with B cell acute lymphoblastic leukemia","volume":"126","author":"Turtle","year":"2015","journal-title":"Blood"},{"key":"R23-20250525","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1016\/j.annonc.2022.05.521","article-title":"Bendamustine is safe and effective for lymphodepletion before tisagenlecleucel in patients with refractory or relapsed large B-cell lymphomas","volume":"33","author":"Ghilardi","year":"2022","journal-title":"Ann Oncol"},{"key":"R24-20250525","first-page":"59","article-title":"Considerations pertaining to cell collection and administration of industry-manufactured autologous CAR-T cells, in relation to French healthcare organization and regulations","volume":"66","author":"Chabannon","year":"2018","journal-title":"Curr Res Transl Med"},{"key":"R25-20250525","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"R26-20250525","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1200\/JCO.20.02477","article-title":"Risk-adapted preemptive tocilizumab to prevent severe cytokine release syndrome after CTL019 for pediatric B-cell acute lymphoblastic leukemia: a prospective clinical trial","volume":"39","author":"Kadauke","year":"2021","journal-title":"J Clin Oncol"},{"key":"R27-20250525","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1093\/cid\/ciy152","article-title":"Cytokine release syndrome grade as a predictive marker for infections in patients with relapsed or refractory B-cell acute lymphoblastic leukemia treated with chimeric antigen receptor T cells","volume":"67","author":"Park","year":"2018","journal-title":"Clin Infect Dis"},{"key":"R28-20250525","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1056\/NEJMoa1215134","article-title":"Chimeric antigen receptor-modified T cells for acute lymphoid leukemia","volume":"368","author":"Grupp","year":"2013","journal-title":"N Engl J Med"},{"key":"R29-20250525","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1111\/bjh.15644","article-title":"Cytokine release syndrome and neurotoxicity after CD19 chimeric antigen receptor-modified (CAR-) T cell therapy","volume":"183","author":"Hay","year":"2018","journal-title":"Br J Haematol"},{"key":"R30-20250525","doi-asserted-by":"crossref","first-page":"745320","DOI":"10.3389\/fimmu.2021.745320","article-title":"Prophylactic tocilizumab prior to anti-CD19 CAR-T cell therapy for non-Hodgkin lymphoma","volume":"12","author":"Caimi","year":"2021","journal-title":"Front Immunol"},{"key":"R31-20250525","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1182\/bloodadvances.2018028720","article-title":"Pharmacologic control of CAR-T cell function using dasatinib","volume":"3","author":"Weber","year":"2019","journal-title":"Blood Adv"},{"key":"R32-20250525","article-title":"Anakinra for refractory CRS or ICANS after CAR T-cell therapy","author":"Gazeau","year":"2023","journal-title":"Transplant Cell Ther"},{"key":"R33-20250525","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.bbrc.2022.01.070","article-title":"Ruxolitinib reduces severe CRS response by suspending CAR-T cell function instead of damaging CAR-T cells","volume":"595","author":"Xu","year":"2022","journal-title":"Biochem Biophys Res Commun"},{"key":"R34-20250525","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s11912-020-00935-6","article-title":"Neurological complications of CAR T cell therapy","volume":"22","author":"Landry","year":"2020","journal-title":"Curr Oncol Rep"},{"key":"R35-20250525","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1136\/practneurol-2020-002550","article-title":"Neurotoxicity-CAR T-cell therapy: what the neurologist needs to know","volume":"20","author":"Neill","year":"2020","journal-title":"Pract Neurol"},{"key":"R36-20250525","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtct.2023.03.006","article-title":"Immune effector cell-associated hemophagocytic lymphohistiocytosis-like syndrome","author":"Hines","year":"2023","journal-title":"Transplant Cell Ther"},{"key":"R37-20250525","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1080\/10428194.2022.2148209","article-title":"Successful treatment of severe cytokine release syndrome after CAR-T therapy by ruxolitinib without compromising CAR-T efficacy","volume":"64","author":"Gu","year":"2023","journal-title":"Leuk Lymphoma"},{"key":"R38-20250525","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1002\/ajh.20202","article-title":"Hemophagocytosis exacerbated by G-CSF\/GM-CSF treatment in a patient with myelodysplasia","volume":"77","author":"Wang","year":"2004","journal-title":"Am J Hematol"},{"key":"R39-20250525","first-page":"20499361211036772","article-title":"Infectious complications of CAR T-cell therapy: a clinical update","volume":"8","author":"Stewart","year":"2021","journal-title":"Ther Adv Infect Dis"},{"key":"R40-20250525","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.jaccao.2020.02.011","article-title":"CAR T cell therapy\u2013related cardiovascular outcomes and management","volume":"2","author":"Ghosh","year":"2020","journal-title":"JACC CardioOncol"},{"key":"R41-20250525","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1182\/blood.2020010543","article-title":"CAR-HEMATOTOX: a model for CAR T-cell-related hematologic toxicity in relapsed\/refractory large B-cell lymphoma","volume":"138","author":"Rejeski","year":"2021","journal-title":"Blood"},{"key":"R42-20250525","doi-asserted-by":"crossref","first-page":"e004475","DOI":"10.1136\/jitc-2021-004475","article-title":"The CAR-HEMATOTOX risk-stratifies patients for severe infections and disease progression after CD19 CAR-T in R\/R LBCL","volume":"10","author":"Rejeski","year":"2022","journal-title":"J Immunother Cancer"},{"key":"R43-20250525","doi-asserted-by":"crossref","first-page":"4715","DOI":"10.1182\/bloodadvances.2022007572","article-title":"CD34+-selected stem cell boost can safely improve cytopenias following CAR T-cell therapy","volume":"6","author":"Mullanfiroze","year":"2022","journal-title":"Blood Adv"},{"key":"R44-20250525","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1182\/bloodadvances.2022008042","article-title":"Hematopoietic stem cell boost for persistent neutropenia after CAR T-cell therapy: a GLA\/DRST study","volume":"7","author":"Gagelmann","year":"2023","journal-title":"Blood Adv"},{"key":"R45-20250525","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1080\/14787210.2021.1855143","article-title":"CAR-T cell therapy and infection: a review","volume":"19","author":"Bupha-Intr","year":"2021","journal-title":"Expert Rev Anti Infect Ther"},{"key":"R46-20250525","doi-asserted-by":"crossref","first-page":"100596","DOI":"10.1016\/j.blre.2019.100596","article-title":"CAR-T \u2013 and a side order of IgG, to go? \u2013 Immunoglobulin replacement in patients receiving CAR-T cell therapy","volume":"38","author":"Hill","year":"2019","journal-title":"Blood Rev"},{"key":"R47-20250525","first-page":"e146743","article-title":"Antibodies to vaccine-preventable infections after CAR-T-cell therapy for B-cell malignancies","volume":"6","author":"Walti","year":"2021","journal-title":"JCI Insight"},{"key":"R48-20250525","doi-asserted-by":"crossref","first-page":"1063986","DOI":"10.3389\/fimmu.2022.1063986","article-title":"Secondary myeloid neoplasms after CD19 CAR T therapy in patients with refractory\/relapsed B-cell lymphoma: case series and review of literature","volume":"13","author":"Zhao","year":"2022","journal-title":"Front Immunol"},{"key":"R49-20250525","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.bbmt.2019.08.003","article-title":"Late events after treatment with CD19-targeted chimeric antigen receptor modified T-cells","volume":"26","author":"Cordeiro","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"key":"R50-20250525","doi-asserted-by":"crossref","first-page":"151216","DOI":"10.1016\/j.soncn.2021.151216","article-title":"The unique symptom burden of patients receiving CAR T-cell therapy","volume":"37","author":"Whisenant","year":"2021","journal-title":"Semin Oncol Nurs"},{"key":"R51-20250525","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1007\/s11912-022-01240-0","article-title":"Rehabilitation needs for patients undergoing CAR T-cell therapy","volume":"24","author":"Obaisi","year":"2022","journal-title":"Curr Oncol Rep"},{"key":"R52-20250525","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.1016\/S1470-2045(19)30493-0","article-title":"Patient-reported quality of life after tisagenlecleucel infusion in children and young adults with relapsed or refractory B-cell acute lymphoblastic leukaemia: a global, single-arm, phase 2 trial","volume":"20","author":"Laetsch","year":"2019","journal-title":"Lancet Oncol"},{"key":"R53-20250525","doi-asserted-by":"crossref","first-page":"1936","DOI":"10.1002\/cam4.3664","article-title":"Acute patient-reported outcomes in B-cell malignancies treated with axicabtagene ciloleucel","volume":"10","author":"Hoogland","year":"2021","journal-title":"Cancer Med"},{"key":"R54-20250525","doi-asserted-by":"crossref","first-page":"390.e1","DOI":"10.1016\/j.jtct.2021.01.003","article-title":"Patient-reported outcomes for cancer patients with hematological malignancies undergoing chimeric antigen receptor T cell therapy: a systematic review","volume":"27","author":"Kamal","year":"2021","journal-title":"Transplant Cell Ther"},{"key":"R55-20250525","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1038\/s41571-020-00456-y","article-title":"Beyond the storm \u2014 subacute toxicities and late effects in children receiving CAR T cells","volume":"18","author":"Shalabi","year":"2021","journal-title":"Nat Rev Clin Oncol"}],"container-title":["Current Opinion in Supportive &amp; Palliative Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/SPC.0000000000000657","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,25]],"date-time":"2025-05-25T18:04:27Z","timestamp":1748196267000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/SPC.0000000000000657"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,7]]},"references-count":55,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.1097\/spc.0000000000000657","relation":{},"ISSN":["1751-4258"],"issn-type":[{"type":"print","value":"1751-4258"}],"subject":[],"published":{"date-parts":[[2023,7,7]]}}}